Yilite Technology Secures Over RMB 1 Billion in Series A Funding to Drive Industry-Leading Growth in Domestic Liquid Chromatography

VCBeat has learned at the earliest opportunity,Suzhou Yilite Technology Co., Ltd.(hereinafter referred to as"Yilite Technology") recently completed its first round of financing exceeding RMB 100 million, with this round led bySpringhill Fund、SND RongshengCo-lead investment,Guofa Venture Capital, Qiaojing Capital, New Alliance Capital, Labtech, Springhill FundPending co-investment,Springhill FundServe as the exclusive financial advisor.

Suzhou Yilite Technology Co., Ltd. boasts over 30 years of experience in translating R&D achievements into production within the field of liquid chromatography instruments and related chromatographic consumables. As a leading enterprise in China, it possesses independent R&D capabilities and has achieved mass production of its products. The company was the first in China to commercially produce domestically made HPLC systems and chromatography columns. It holds a commanding lead in the domestic market share of Chinese-made HPLC systems and, through the strategic deployment of more than 100 core patents, has realized independent intellectual property rights and localization for core components of liquid chromatography systems.

Furthermore, Suzhou Yilite Technology Co., Ltd. is the lead enterprise in the formulation of national standards for liquid chromatography and has presided over the drafting of multiple HPLC national standards. The successful completion of this financing transaction reflects the capital market’s recognition of the company’s past achievements and its future development prospects.

The company focuses on laboratory physicochemical analysis, upstream purification in emerging biotechnology, and clinical analytical diagnostics, continuously investing in the research and development of a series of instrumental products and corresponding chromatography consumables. For many years, the company has been committed to achieving "true domestication" of analytical instruments through integrated product development and manufacturing, having fully mastered supply chain management, intelligent manufacturing processes, and mass production technologies. This ensures product stability while enabling lean control over product costs.

In the process of expanding downstream scenarios and achieving full coverage of application scenarios for domestically produced liquid chromatography instruments, the company has secured a leading position in the industry. The company ranks among the top in its domestic peer group in market development and brand promotion, with “Yilite” established as the leading domestic brand in the sector. It has successfully spearheaded multiple national-level scientific and technological R&D projects and has been included in the list of “High-Quality Domestic Instruments.”

In the field of laboratory physicochemical analysis, the company’s series of liquid chromatography products ranks No. 1 in market share in China. To date, cumulative sales of domestically produced instruments have exceeded 15,000 units, with over 190,000 chromatography columns sold. The company is a leading enterprise in China with extensive experience in the mass production of both chromatographic instruments and consumables, holding more than 50 technical patents. To meet customers’ differentiated needs, the company offers high-, mid-, and low-end product lines, covering various categories such as HPLC, UHPLC, and LC/MS. Its products have already entered the international market and gained widespread recognition and acclaim.

Driven by the downstream application demands arising from the development and transformation of emerging biotechnologies, the company has developed a series of "end-to-end" solutions for analysis, purification, and separation, scaling from laboratory to manufacturing, specifically tailored for customers engaged in the R&D and production of peptides, mRNA, and small nucleic acids. As one of the earliest manufacturers in China dedicated to the development and industrialization of medium- and high-pressure preparative chromatography, the company offers a comprehensive product portfolio that includes medium- and high-pressure constant-flow pumps with flow rates ranging from 20 mL/min to 3,000 mL/min, preparative detectors, automatic fraction collectors, and various preparative consumables. This enables rapid response to application-specific needs, translating them into final products and solutions that deliver value to customers.

The company has successfully launched liquid chromatography products specifically designed for clinical applications, including those for glycated hemoglobin and therapeutic drug monitoring. Leveraging over two decades of extensive expertise in the domestic development of liquid chromatography equipment, the company has developed a series of dedicated chromatography analyzers characterized by “low cost” and “foolproof operation.” These products address the prevailing challenges of “high instrument costs” and “complex operations” in current clinical practice, offering a fundamental solution that facilitates deeper penetration of liquid chromatography and liquid chromatography-tandem mass spectrometry (LC-MS/MS) into clinical applications.

Li Yabo, CEO of Suzhou Yilite Technology Co., Ltd.Statement: We extend our sincere gratitude to the investors for their recognition and support of Yilite! As a leading enterprise in China’s domestic liquid chromatography sector, Yilite has secured a prominent position by virtue of its reliable product quality, high rate of localization, and excellent service system. The proceeds from this round of financing will be primarily allocated to new product development, construction of new facilities, establishment of overseas distribution channels, and daily operations. Meanwhile, Suzhou Yilite Technology Co., Ltd. will continue to deepen cooperation and strategic layout with renowned enterprises both domestically and internationally, continuously build a comprehensive product portfolio, expand downstream innovative applications and international channels, and strive to become a leading global brand in the field of liquid chromatography.

Hu Xuyu, Managing Partner of Springhill FundIt was stated that liquid chromatography is a critical component of the life sciences, clinical diagnostics, and biopharmaceutical industrial chains, characterized by a vast market potential and high technical barriers, with the market currently dominated by imported products. As a leading domestic brand, Suzhou Yilite Technology Co., Ltd. plays a pivotal role in breaking import monopolies, advancing domestic substitution, and driving globalization. The company has established a comprehensive product portfolio encompassing liquid chromatography, gas chromatography, and mass spectrometry, providing end-to-end solutions to downstream customers and creating value for them. We look forward to the company’s continued global expansion, contributing to global innovation.

SND RongshengStated: As a leader in domestically produced liquid chromatography, Suzhou Yilite Technology Co., Ltd. not only continues to innovate technologically, leading the industry frontier, but has also established an outstanding reputation in the market. We are well aware that the success of Suzhou Yilite Technology Co., Ltd. is no accident; rather, it stems from its profound technical accumulation, exceptional R&D capabilities, and keen insight into market demands. The success of this financing round is not only an affirmation of Suzhou Yilite Technology Co., Ltd.'s past efforts but also a recognition of its future potential. We believe that with the injection of new capital, Suzhou Yilite Technology Co., Ltd. will have more opportunities and resources to achieve greater breakthroughs and lead the liquid chromatography industry toward even more significant leapfrog development.

Guofa Venture CapitalStated: Guofa Venture Capital maintains a long-term bullish outlook on the localization of high-end liquid chromatography instruments, valuing Suzhou Yilite Technology Co., Ltd.’s demonstrated systematic product development capabilities and market expansion efficiency. In the future, Guofa Venture Capital will provide strong support to Suzhou Yilite Technology Co., Ltd. in capital operations and industrial chain resource integration, thereby facilitating the company’s sustained development.

Qiao Jing CapitalQiao Jing Capital stated: "We are deeply honored to support the development of domestically produced precision instruments. As a leading enterprise in the independent R&D and manufacturing of high-performance liquid chromatography (HPLC) systems, Suzhou Yilite Technology Co., Ltd. remains committed to application-oriented R&D. By continuously refining instrument performance and introducing innovations based on long-term feedback from end-users, the company strives to enhance user experience. Its core technical team possesses solid expertise, operates with efficiency and pragmatism, and demonstrates profound insights into both the industry and technology. We look forward to seeing Yilite’s comprehensive analytical instrument solutions further expand their reach among domestic and international enterprises as well as research institutions through the team’s dedicated efforts. Qiao Jing Capital will continue to spare no effort in accompanying and empowering the company’s growth."

Lianxin CapitalStatement: New Alliance Capital is honored to participate in this round of financing for Yilite Technology. As a leading domestic brand in liquid chromatography, Yilite has cultivated deep expertise within the industry over many years. Its team possesses extensive experience in production and R&D, with robust research capabilities and products that have gained widespread recognition over the years. We are highly optimistic about Yilite’s growth potential as a liquid chromatography platform and look forward to its continued launch of more impactful products, enabling Chinese-made instruments to reach a broader global stage.

Jifeng Capital, founded in 2015, is a premier venture capital firm dedicated to the healthcare and medical sectors. By empowering enterprises through comprehensive value-added services and a global perspective, we drive innovation with the aim of delivering long-term value to the development of the healthcare industry and human health. Remaining true to our entrepreneurial roots, we consistently uphold the spirit of “professionalism, humility, and diligence.” We are committed to serving entrepreneurs as long-term strategic partners, helping them establish a strong foothold in China while embracing a global vision to build great enterprises.

SND Financial Holding has a registered capital of RMB 5.1 billion and total assets exceeding RMB 20 billion. It is a state-owned financial holding group directly under the Administration Committee of Suzhou New District. SND Financial Holding operates four core business segments: equity investment, non-bank financial services, capital market services, and digital finance development. The company has established a comprehensive financial service system characterized by coordinated development and integrated interaction, striving to become a first-class modern financial holding enterprise. SND Rongsheng, a market-oriented private equity fund management subsidiary of SND Financial Holding, primarily focuses on industries such as biopharmaceuticals and medical devices, high-end equipment manufacturing, and new materials. With currently managed funds totaling approximately RMB 1.6 billion, it has successfully facilitated the listing of Huasheng Lithium (688353) and Canadian Solar (688472) on the STAR Market.

Suzhou International Development Venture Capital Holding Co., Ltd. (hereinafter referred to as “Guofa VC”) was established in May 2008 with a registered capital of RMB 3.8 billion. It is a key component of Suzhou’s initiative to build Guofa Group into an integrated local financial platform encompassing banking, insurance, securities, trust, venture capital, and guarantee services. The company focuses on expanding into the financial asset management sector, integrating financial innovation with wealth management. Its business scope covers VC and PE investments, insurance fund management, urban development funds, and government guidance funds, among others. It manages over 20 funds dedicated to infrastructure, urban development, and cultural tourism industries, with total assets under management amounting to approximately RMB 140 billion.

Qiao Jing Capital focuses on early-stage investments in the healthcare and medical industry, with a particular emphasis on medical devices, biopharmaceuticals, and innovative biotechnologies. In the field of medical devices, it has strategically invested in high-value consumables such as Allgens Medical (688613), Tianzhu Ruichang (aortic stent grafts), Kangfeng Biotechnology (cryoablation for atrial fibrillation), and Tianhong Shengjie (peripheral vascular intervention). In the biopharmaceutical sector, it has targeted dynamic innovative drug companies, including Zhidao Biotechnology (a protein-based innovative drug R&D platform) and Genfleet Therapeutics (a technology platform for large and small molecule drugs). Qiao Jing Capital consistently adheres to value investing based on clinical needs in the medical field, fostering new medical technologies to provide superior solutions for clinical practice in China and contributing to the advancement of global healthcare.

New Alliance Capital was established in August 2008 as a fund management company specializing in private equity and venture capital investments. Currently, New Alliance Capital manages multiple funds, with total assets under management exceeding RMB 10 billion.

New Alliance Capital’s primary investment focus spans sectors such as technology, media, and healthcare, covering all stages from early-stage to growth-stage and mature-stage companies. To date, it has completed over 160 investments, with nearly 40 portfolio companies having gone public or listed on exchanges domestically and internationally, nurturing a cohort of industry leaders.

Beijing Labtech Instruments Co., Ltd. was established in 2002 and is a technology-driven company specializing in the research and development, manufacturing, and sales of laboratory analytical instruments.

Since its inception, Beijing Labtech Instruments Co., Ltd. has been committed to providing comprehensive laboratory solutions—including practical and reliable laboratory analytical instruments, intelligent automated sample preparation equipment, laboratory engineering services, and consumables—to clients across numerous industries such as environmental monitoring, food safety, disease control, semiconductor testing, life sciences, energy and chemical engineering, nuclear environmental protection, public security and judicial forensics, geology and mineral resources, and materials research. It is one of the leading global suppliers of laboratory analytical instruments capable of integrating diverse, multi-functional sample preparation technologies with fully automated experimental analysis and detection platforms into cohesive, fully automated analytical instrument systems.

7 Pioneering is an emerging domestic early-stage incubation and investment platform, focusing on original innovation opportunities in the fields of technology, medical technology, and life sciences.

Leveraging deep expertise in cross-disciplinary technologies, keen insight into capital trends, and robust financial support resources, we facilitate the commercialization and growth of a portfolio of original technologies under “strategic business direction” and “consensus-driven capital empowerment.”